In short
Mesenchymal stromal cells (MSCs), a type of adult stem cell, are at the forefront of regenerative medicine research. These cells, which can be cultured outside the body, are being investigated in various clinical trials for their potential to treat a wide range of conditions. From graft-versus-host disease to multiple sclerosis and bone regeneration, MSCs offer promising therapeutic possibilities due to their ability to differentiate into various cell types and modulate the immune system.
At a glance
- Cell Type
- Mesenchymal Stromal Cells (MSCs), ex vivo cultured
- Main Conditions Studied
- Steroid-refractory acute Graft-versus-host Disease, Progressive Multiple Sclerosis, Alveolar bone defects
- Administration Routes
- Intravenous, Intrathecal, Transplantation
- Trial Phases
- Phase II, Phase III
- Key Objectives
- Assess safety and efficacy, evaluate overall response rates, investigate neuroregenerative potential, bone regeneration capabilities
- Patient Age Range
- Varies by study: from 12 years to adults
- Follow-up Duration
- 6 months to 24 months
- Primary Endpoints
- Overall response rate, changes in neurophysiological parameters, bone width changes
- Safety Monitoring
- Adverse events, infections, changes in vital signs and laboratory results
What are Mesenchymal Stromal Cells (MSCs)?
Mesenchymal Stromal Cells (MSCs), also known as mesenchymal stem cells, are a type of adult stem cell that can be derived from various tissues in the body. These cells have the unique ability to differentiate into different cell types and possess immunomodulatory properties, making them a promising candidate for treating various medical conditions.
MSCs are being studied under different names, including:
- ImmuStem
- Ex vivo cultured human mesenchymal stromal cells
- MC0518 (a specific product under investigation)
Medical Conditions Treated with MSCs
Clinical trials are exploring the use of MSCs in treating several medical conditions, including:
- Steroid-refractory Acute Graft-versus-Host Disease (SR-aGvHD): This is a serious complication that can occur after allogeneic stem cell transplantation, where the donor's immune cells attack the recipient's tissues.
- Progressive Multiple Sclerosis (MS): A chronic neurological condition affecting the central nervous system.
- Alveolar Bone Augmentation: A procedure to increase bone volume in the jaw for dental implant placement.
How are MSCs Administered?
The administration of MSCs varies depending on the condition being treated:
- For SR-aGvHD, MSCs are typically administered intravenously (through a vein).
- In the case of progressive MS, MSCs are injected intrathecally (into the spinal fluid).
- For alveolar bone augmentation, MSCs are applied directly to the site of bone defect during a surgical procedure.
Efficacy of MSC Treatment
The efficacy of MSC treatment is being evaluated in various clinical trials:
- In SR-aGvHD, researchers are assessing the overall response rate at 28 days after treatment, comparing MSCs to the best available therapy.
- For progressive MS, the primary objective is to investigate neuroregenerative efficacy as measured by neurophysiological parameters.
- In alveolar bone augmentation, efficacy is measured by the change in bone width and the ability to place dental implants in the reconstructed area.
Safety Considerations
Safety is a crucial aspect of MSC treatment. Clinical trials are closely monitoring:
- Adverse events and serious adverse events
- Changes in vital signs
- Physical examination findings
- Clinical laboratory results
It's important to note that MSC treatment may not be suitable for everyone. Exclusion criteria often include:
- History of malignancy
- Uncontrolled infections
- Severe respiratory diseases
- Pregnancy or breastfeeding
Ongoing Research and Future Directions
Several clinical trials are currently underway to further investigate the potential of MSCs:
- The BALDER Trial is studying MC0518 in pediatric patients with SR-aGvHD.
- The IDUNN Trial is evaluating MC0518 in adult and adolescent patients with SR-aGvHD.
- The SMART-MS study is exploring the use of autologous MSCs in progressive multiple sclerosis.
- A multicentre clinical trial is investigating alveolar bone augmentation using MSCs and biphasic calcium phosphate granules.
These ongoing studies aim to provide more comprehensive data on the efficacy, safety, and long-term outcomes of MSC treatment across various medical conditions.